Patents by Inventor Mark Leid

Mark Leid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CTIP2 expression in squamous cell carcinoma
    Patent number: 8071815
    Abstract: The present disclosure provides methods of diagnosing and staging squamous cell carcinomas, for instance head and neck (HNSCC), by detecting chicken ovalbumin upstream promoter-transcription factor-interacting protein 2 (CTIP2) expression. For example, it is demonstrated herein that expression of CTIP2 is increased in SCC relative to a corresponding normal sample. Also included are kits for detecting SCC, as well as methods for identifying CTIP2 inhibitors.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: December 6, 2011
    Inventors: Arup Kumar Indra, Gitali Indra, Joseph Abecassis, Mark Leid
  • CTIP2 EXPRESSION IN SQUAMOUS CELL CARCINOMA
    Publication number: 20100015625
    Abstract: The present disclosure provides methods of diagnosing and staging squamous cell carcinomas, for instance head and neck (HNSCC), by detecting chicken ovalbumin upstream promoter-transcription factor-interacting protein 2 (CTIP2) expression. For example, it is demonstrated herein that expression of CTIP2 is increased in SCC relative to a corresponding normal sample. Also included are kits for detecting SCC, as well as methods for identifying CTIP2 inhibitors.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Inventors: Arup Kumar Indra, Gitali Indra, Joseph Abecassis, Mark Leid
  • Induction of apoptosis in cancer cells
    Patent number: 7053071
    Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: May 30, 2006
    Assignee: The Burnham Institute
    Inventors: Marcia Dawson, Joseph A. Fontana, Xiao-kun Zhang, Mark Leid, Ling Jong, Peter D. Hobbs
  • Heterodimeric nuclear receptors proteins, genes encoding same, and usage thereof
    Patent number: 6635429
    Abstract: The present invention is based in part on the novel observation that two different types of nuclear receptors, retinoic acid receptors (RAR) and thyroid receptors (TR) dimerize with a RX receptor (RXR) to form a heterodimer which is capable of binding to retinoic acid response elements (RARE) or thyroid receptor response elements (TRE) at physiological conditions. In addition, the present invention discloses that RXR homodimers are capable of binding to RARE's. Based on this observation, the present invention provides novel dimeric proteins, methods of identifying agents capable of binding the dimers of the present invention, methods of identifying DNA sequences capable of being bound by the dimers and methods to identify RA metabolic enzymes and proteins which are required for the activation function of nuclear receptors.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: October 21, 2003
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, Bristol-Myers Squibb Company
    Inventors: Mark Leid, Philippe Kastner, Pierre Chambon
  • Induction of apoptosis in cancer cells
    Publication number: 20030176506
    Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.
    Type: Application
    Filed: December 2, 2002
    Publication date: September 18, 2003
    Inventors: Marcia J. Dawson, Joseph A. Fontana, Xiao-kun Zhang, Mark Leid, Ling Jong, Peter D. Hobbs
  • Induction of apoptosis in cancer cells
    Patent number: RE42700
    Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis of apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: September 13, 2011
    Assignees: Sanford-Burnham Medical Research Institute, Oregon State University, SRI International, Molecular Medicine Research Institute, Department of Veterans Affairs, Wayne State University
    Inventors: Marcia Dawson, Joseph A. Fontana, Xiao-Kun Zhang, Mark Leid, Ling Jong, Peter D. Hobbs